Regression of human coronary artery plaque is associated with a high ratio of (18-hydroxy-eicosapentaenoic acid + resolvin E1) to leukotriene B4
Welty FK, Schulte F, Alfaddagh A, Elajami TK, Bistrian BR, Hardt M
FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 50 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (clasificado por nuestro filtro de IA)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Heart, Lung, and Blood Institute
- Gobierno
- National Center for Advancing Translational Sciences
- Gobierno
- NCATS NIH HHS
- Gobierno
- NHLBI NIH HHS
- Subvenciones
- National Center for Advancing Translational Sciences (UL1TR001102); National Heart, Lung, and Blood Institute (P50-HL083813)
Según 4 financiadores declarados.
Publicación
- Publicado
- 2021-03-22 · FASEB J · vol. 35 · número 4 · pág. e21448
- Editorial
- Wiley
- Citado
- 54 citas · más que el 96% de estudios similares · 4.7× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 44 trabajos
- Acceso
- Acceso abierto (copia en repositorio)
- Áreas de investigación
- Fatty Acid Research and Health · Eicosanoids and Hypertension Pharmacology · Cholesterol and Lipid Metabolism
- Palabras clave
- Eicosapentaenoic acid, Internal medicine, Docosahexaenoic acid, Medicine, Cardiology, Chemistry, Fatty acid, Biochemistry, Polyunsaturated fatty acid
- MeSH
- humans, docosahexaenoic acids, eicosapentaenoic acid, leukotriene b4, prostaglandins, hydroxymethylglutaryl-coa reductase inhibitors, aged, middle aged, female, male, plaque, atherosclerotic
6 autores
- Francine K. Welty🇺🇸 · autor de correspondenciaBeth Israel Deaconess Medical Center
- Fabian Schulte🇺🇸Harvard University; The Forsyth Institute
- Abdulhamied Alfaddagh🇺🇸Beth Israel Deaconess Medical Center
- Tarec K. Elajami🇺🇸Beth Israel Deaconess Medical Center
- Bruce Ryan Bistrian🇺🇸Beth Israel Deaconess Medical Center
- Markus Hardt🇺🇸Harvard University; The Forsyth Institute
Resumen
El texto original del estudio, en el idioma en que se publicó.
Inflammation in arterial walls leads to coronary artery disease (CAD). We previously reported that a high omega-3 fatty index was associated with prevention of progression of coronary atherosclerosis, a disease of chronic inflammation in the arterial wall. However, the mechanism of such benefit is unclear. The two main omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are precursors of specialized pro-resolving lipid mediators (SPMs)-resolvins and maresins-which actively resolve chronic inflammation. To explore whether SPMs are associated with coronary plaque progression, levels of SPMs and proinflammatory mediators (leukotriene B4 [LTB4 ] and prostaglandins) were measured using liquid chromatography-tandem mass spectrometry in 31 statin-treated patients with stable CAD randomized to either EPA and DHA, 3.36 g daily, or no EPA/DHA (control). Coronary plaque volume was measured by coronary computed tomographic angiography at baseline and at 30-month follow-up. Higher plasma levels of EPA+DHA were associated with significantly increased levels of two SPMs-resolvin E1 and maresin 1-and 18-hydroxy-eicosapentaenoic acid (HEPE), the precursor of resolvin E1. Those with low plasma EPA+DHA levels had a low (18-HEPE+resolvin E1)/LTB4 ratio and significant plaque progression. Those with high plasma EPA+DHA levels had either low (18-HEPE+resolvin E1)/LTB4 ratios with significant plaque progression or high (18-HEPE+resolvin E1)/LTB4 ratios with significant plaque regression. These findings suggest that an imbalance between pro-resolving and proinflammatory lipid mediators is associated with plaque progression and potentially mediates the beneficial effects of EPA and DHA in CAD patients.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.